In the T2D+ group, Gal-3 concentration did not differ significantly between patients treated with metformin only (n = 16) and those treated with insulin ± another oral drug other than metformin (n = 15) (median 12.68, IQR 5.40 vs. median 11.37, IQR 8.22, p = 0.363). The gene discussed is LGALS3; the disease is type 2 diabetes mellitus.